"Teicoplanin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Glycopeptide antibiotic complex from Actinoplanes teichomyceticus active against gram-positive bacteria. It consists of five major components each with a different fatty acid moiety.
| Descriptor ID |
D017334
|
| MeSH Number(s) |
D09.400.420.900 D12.644.233.900
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Teicoplanin".
Below are MeSH descriptors whose meaning is more specific than "Teicoplanin".
This graph shows the total number of publications written about "Teicoplanin" by people in this website by year, and whether "Teicoplanin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2006 | 2 | 1 | 3 |
| 2011 | 1 | 0 | 1 |
| 2017 | 8 | 0 | 8 |
| 2018 | 2 | 2 | 4 |
| 2019 | 2 | 1 | 3 |
| 2020 | 4 | 1 | 5 |
| 2021 | 4 | 1 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Teicoplanin" by people in Profiles.
-
Can treatment with teicoplanin improve the prognosis of COVID-19 patients? Int J Clin Pract. 2021 Nov; 75(11):e14752.
-
Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs. Drug Des Devel Ther. 2021; 15:3349-3378.
-
National surveillance of antimicrobial susceptibilities to dalbavancin, telavancin, tedizolid, eravacycline, omadacycline and other comparator antibiotics and serotype distribution of invasive Streptococcus pneumoniae isolates in adults: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) programme in 2017-2020. J Glob Antimicrob Resist. 2021 09; 26:308-316.
-
Available drugs and supplements for rapid deployment for treatment of COVID-19. J Mol Cell Biol. 2021 07 06; 13(3):232-236.
-
The role of teicoplanin in the treatment of SARS-CoV-2 infection: A retrospective study in critically ill COVID-19 patients (Tei-COVID study). J Med Virol. 2021 Jul; 93(7):4319-4325.
-
The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives. Expert Rev Anti Infect Ther. 2021 09; 19(9):1125-1134.
-
Dalbavancin: novel candidate for COVID-19 treatment. Cell Res. 2021 03; 31(3):243-244.
-
Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics. Front Cell Infect Microbiol. 2020; 10:589505.
-
Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models. Cell Res. 2021 01; 31(1):17-24.
-
Possible treatment and strategies for COVID-19: review and assessment. Eur Rev Med Pharmacol Sci. 2020 12; 24(23):12593-12608.